In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Ingevity Corporation’s current price significantly exceeds its high-confidence PERT-weighted fair value by 47.5%, indicating potential overvaluation. Financial health scores reveal poor profitability and leverage despite strong growth, increasing risk. Monte Carlo analysis shows 100% downside risk below the current price, suggesting elevated volatility and uncertainty.